European advisory committee backs label update for Nordisk’s Tresiba

Shares in Novo Nordisk (NYSE:NVO) were up 2% this morning after the European Medicines Agency’s Committee for Medicinal Products for Human Use backed the company’s application for a label update to its Tresiba insulin injection.

The company submitted an application in November to add data from 2 studies to the medication’s label. The final ruling is expected to come from the committee in 60 days.

Get the full story at our sister site, Drug Delivery Business News.

The post European advisory committee backs label update for Nordisk’s Tresiba appeared first on MassDevice.

from MassDevice http://ift.tt/2mzoBQx